C difficile risk
Oral Bioavailability


Defined criteria for use and/or important safety considerations. See below for more information.

2 g IV q8h

2 g IV q4h

CrCl > 50 mL/minCrCl 10 - 50 mL/minCrCl < 10 mL/minNo renal adjustment required2 g IV q8-12h2 g IV q24h

CrCl > 50 mL/minCrCl 30 - 50 mL/minCrCl 10 - 30 mL/minCrCl < 10 mL/minNo renal adjustment required2 g IV q6h2 g IV q8h2 g IV q12h

Most IndicationsCNS Infections2 g IV q24h

  • Give dose after dialysis on HD days2 g IV q12-24h

  • Give dose after dialysis on HD days

Most IndicationsCNS infections1 - 2 g IV q24h2 g IV q12-24h

Most IndicationsCNS infections2 g IV q12h 2 g IV q6-8h

General Information

  • May be used in place of ceftriaxone for patients with biliary sludging or cholestatic hepatitis.

  • EMPIRIC therapy of severely ill patients with suspected Gram-negative infection

  • Documented Gram-negative infection resistant to 1st and 2nd generation cephalosporins

  • Meningitis

  • Spontaneous bacterial peritonitis, community-acquired secondary peritonitis (or hospital acquired with no previous antimicrobial therapy), or intra-abdominal abscess.

  • Community acquired pneumonia

Does not cover Pseudomonas and other resistant Gram-negatives, ESBLs or AmpC producing Enterobacteriaceae

  • Neutropenia

  • Abnormalities in liver enzymes

  • Diarrhea, C. difficile

Prefer ceftriaxone for CNS infection in renal failure

Antimicrobial class: 3rd Generation Cephalosporin

Pregnancy category: B

Average serum half life: 1.5 hours

Biliary penetration: Moderate

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.